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Purpose: Graves’ ophthalmopathy (GO) is an autoimmune condition primarily managed with
prolonged courses of glucocorticoids, which can be associated with significant side effects.
Orbital radiation therapy (RT) is an alternative treatment that has shown variable efficacy in
improving orbital and visual symptoms. In this study, the therapeutic benefit of RT was
evaluated in terms of patient’s ability to taper their corticosteroid requirements, which may
better reflect the proposed mechanism of RT and provide a clinically relevant response
endpoint.
Methods and materials: This is a retrospective review of consecutive patients treated with
orbital RT for GO between 2000 and 2010 at a single tertiary hospital with a dedicated
ocular radiation therapy clinic. The primary measure of treatment response was defined as the
ability to taper glucocorticoids following RT without any further exacerbation of orbitopathy
symptoms. Additional endpoints including ocular symptoms (diplopia, proptosis, visual acuity,
extraocular movement) and need for surgical intervention were reported.
Results: Of 86 eligible patients, with a mean follow-up of 9.3 months, 81 (94%) patients
responded to RT. Of patients taking corticosteroids at baseline, 91% were able to taper off
corticosteroids completely and the remaining patients had decreased their doses by 83%.
Diplopia, visual acuity, and extraocular movements improved in 29%, 81%, and 58% of
patients, respectively. The median reduction in proptosis was 2.5 mm and 2 mm in the left
and right eyes, respectively (range, −18 mm to 23 mm).Conflicts of interest: None.
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duration of corticosteroid therapy for patients with GO while improving ocular symptoms,
including proptosis and diplopia. Prospective research should consider using corticosteroid
requirement as a measure of response to orbital RT for GO.
© 2014 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation
Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Graves’ ophthalmopathy (GO) is clinically present in
20%-25% of patients at the time of their diagnosis of
hyperthyroidism.1 A significantly larger proportion of
patients with hyperthyroidism, up to 71%, have radiologic
evidence of extraocular muscle enlargement on magnetic
resonance imaging consistent with GO but no bothersome
reported symptoms.2 In the general population, the
estimated incidence of GO is 16 women and 3 men per
100,000 population per year.3
The natural history of GO is widely variable with
spontaneous remission seen in some patients and persistent
or progressive disease seen despite medical treatment in
others.4 Glucocorticoid therapy has been the primary
treatment for patients suffering from symptomatic GO.5,6
Studies comparing oral and intravenous corticosteroids
have reported varying adverse event rates among groups
with weight gain, hypertension, and development of
cushingoid features as common adverse events in the
oral corticosteroid group and flushing, dyspepsia, and
palpitations reported in the intravenous group.7-10 The risk
of any adverse event was related to the dose and duration
of glucocorticoid treatment.11
Given the adverse events related to glucocorticoid
treatment, orbital radiation therapy has been investigated
as an alternative therapy for GO. However, studies to date
have reported a wide range of responses to radiation
therapy for GO.12-15 This is, at least in part, due to variable
endpoint measures of response to radiation therapy and
inclusion of patients at all stages of disease in these
studies. Response endpoints used in prior studies include
reduction in proptosis or orbital muscle bulk, and
improvement in diplopia. Although these endpoints are
clinically important, as they do not reflect the proposed
mechanism of radiation therapy (RT), a suppression of the
inflammatory process, use of these measures as primary
endpoints may underestimate the efficacy of radiation
therapy. This study defines response to RT as the ability of
patients to taper glucocorticoids following RT without
further exacerbation of their orbitopathy symptoms. This
endpoint may better reflect the proposed effect of RT to
suppress the inflammatory process and provides a
clinically relevant response measure that accounts for the
association between the dose and duration of glucocorti-
coid therapy and its related toxicities.Methods and materials
This is a retrospective review of consecutive
patients treated with orbital RT for GO between
2000 and 2010 at a single tertiary hospital with a
dedicated ocular radiation therapy clinic. Research was
completed in accordance with local research ethics
board requirements. The following baseline data were
collected: dose of steroids at consultation and initiation
of RT; prior radioactive iodine treatment; and orbital
decompression surgery, diplopia, proptosis, visual
acuity, and extraocular movements. Follow-up data
included steroid dose based on patient history and
prescription records, diplopia reported by the patient
history and observed during the physical exam,
proptosis based on clinical exam including exophthalm-
ometer readings, visual acuity, and extraocular move-
ments based on physical exam, and any ocular surgery
(decompression, muscle-corrective, and oculoplastic
surgery). Standard clinical follow-up generally included
assessment after RT at 3-month intervals for the first
18 months then yearly. However, based on patient
preference some patients were followed initially in the
Ocular Radiotherapy Clinic then discharged to their
ophthalmologist or endocrinologist with a corticosteroid
tapering plan and instructions to the patient and
referring physician to return to the clinic upon
recurrence of symptoms at any point after RT. Patients
with either follow-up regimen were considered to have
full follow-up. Patients who did not return for their
follow-up appointments and did not have a clear
corticosteroid tapering plan while being followed by
their referring physician, were censored due to missing
information in the statistical analysis.
The primary endpoint was response to RT, defined as
the ability to wean down or off glucocorticoids at 6 months
following completion of RT without any further GO flares
after 6 months from completion of RT. “Flare” was
defined as a need for further intervention (increase in
steroids or surgery) due to increased symptoms any time
beyond 6 months after completion of RT. Descriptive
statistics were used to report steroid requirements and any
further incidence of flares, as well as endpoints that have
been reported previously in publications including
changes in diplopia, proptosis, visual acuity, and extrao-
cular movements.
Table 1 Characteristics of the study population at initiation
of radiation therapy
Characteristic No. (%)
Sex
Male 38 (44)
Female 48 (56)
Prior radioactive iodine treatment 26 (30)
Steroid use
Any steroids 69 (80)
On steroids at start of RT 60 (70)
Average daily prednisone dose at
start of RT (range)
38 mg
(5 mg-100 mg)
Symptoms
Diplopia 52 (84)
Proptosis 59 (95)
Decreased visual acuity 51 (88)
Restricted extraocular movements 64 (82)
Orbital decompression prior to RT 19 (22)
RT, radiation therapy.
(A)
(C)
Figure 1 Representative images of a radiation therapy plan for Grave
showing the clinical target volume encompassing the extraocular musc
dose distribution through both orbits, sparing the lenses and anterior ch
the patient in an immobilization mask with field borders. (D) Sagittal C
orbital muscles, sparing the anterior globes and brain.
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There were 86 consecutive patients who met eligibility
criteria, with 38 men (44%) and 48 women (56%) with
median ages of 50 (range, 34-81) and 54 (range, 35-86)
years, respectively (Table 1). All 86 patients received a
total dose of 2000 cGy delivered in 10 daily fractions over
2 weeks to both orbits (except 1 patient who only received
radiation to her right orbit [Fig 1]). The majority of patients
(n = 69) had been taking prednisone for varying durations
prior to the initial radiation therapy consultation and were
generally referred due to difficulty tapering their cortico-
steroids due to exacerbation of orbitopathy symptoms
upon tapering. The mean dose of prednisone at the time of
initial consultation was 47.5 mg daily (range, 7.5 mg-100
mg). Among the 13 (15%) patients who had never used
steroids prior to consultation, a variety of contraindications
(including glaucoma, hypertension, and diabetes) to
steroids were noted.(B)
(D)
s’ ophthalmopathy. (A) Axial computed tomographic (CT) image
les delineated in red. (B) Axial CT image showing the radiation
ambers of both orbits. (C) Sagittal image of the skin rendering of
T image showing the radiation dose distribution focused on the
Figure 2 Proportional corticosteroid requirement following
radiation therapy. The data points represent the mean steroid dose
of patients at a given month as a proportion of their total steroid
dose at initiation of orbital radiation therapy. Error bars represent
95% confidence intervals. The increase in range of the
confidence interval at 18 months is due to 1 patient whose
steroid dose increased by the end of follow-up.
Table 3 Symptom outcomes postorbital radiation therapy
(RT)
Outcome No. (%)
Diplopia
Improved 16 (31)
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At the start of radiation therapy, 60 patients were taking
prednisone at a mean dose of 38 mg (range, 5 mg-100 mg)
per day. At baseline, 51 patients had impaired visual
acuity, 62 patients had documentation of diplopia of which
52 (84%) complained of this symptom, and 62 patients had
documented proptosis of which 59 (95%) had exophthal-
mometer measurements. Documented limitation in extra-
ocular movements was reported in 78 patients of which 64
(82%) reported symptomatic limitation in their extraocular
movements. Nineteen patients had orbital decompressive
surgery prior to receiving orbital radiation therapy, mainly
due to vision loss despite medical intervention.
Radiation treatment response and toxicities
With an average in-clinic follow-up of 9.3 months
(range, 1-36.5 months), 81 (94%) patients responded to
RT. Five patients (6%) failed RT and required further
intervention for progressive symptoms following RT.
There were no patients with a documented late flare of GO
after 18 months following orbital RT (Table 2). There were
no grade 2 or greater acute or late radiation-related
toxicities observed within this study cohort.
Among patients with full follow-up who took corticoste-
roids at induction of RT, 90.9% completely weaned off
corticosteroids by the end of follow-up. The average percent
decrease of their steroid dose, relative to their dose at
induction of radiation therapy, was 96.1% (Fig 2). Of the
patients who were unable to fully taper steroids, their steroid
requirements were reduced to 26.7% of their doses at the start
of RT. Only 1 of these patients required a small increase in
steroid dose at the end of follow-up. There was incomplete
documentation of corticosteroid doses in 11 patients and they
were censored in the statistical analysis; 1 of these patients
was transitioned to palliative care due to development of
rapidly progressive anaplastic thyroid cancer.Table 2 Steroid therapy after orbital radiation therapy
Characteristic No. (%)
Able to discontinue steroids 40 (91)
Unable to discontinue steroids 4 (9)
Average percent decrease in
steroid dose
96.10%
Average percent decrease in steroid
dose in patients who were unable to fully
reduce their steroid dose
83.30%
Off all steroids by 6 mo 38 (84.4)
Failed radiation therapy 5 (7.5)
Flare of GO at N18 mo 0
Patients censored from statistical analysis due to
missing information
11 (18)In the subgroup of 19 patients who received orbital
decompressive surgery prior to orbital RT, 5 patients
completely tapered off corticosteroids and 2 patients had a
50% reduction in their corticosteroid doses by last follow-
up. Seven patients had no clear documentation of
corticosteroid use and 5 patients were not taking
corticosteroids at initiation of RT.Worsened 2 (4)
Proptosis
Median improvement in
the left eye (range)
2.5 mm
(−18 mm to 23 mm)
Median improvement in
the right eye (range)
2.0 mm
(−18 mm to 23 mm)
Visual acuity
Improved 30 (81)
Worsened 6 (16)
Extraocular movement restriction
Improved 29 (58)
Worsened 5 (10)
Orbital decompression
surgery after RT
5 (6)
Eyelid oculoplastic surgery
after RT
14 (16)
Muscle corrective surgery
after RT
16 (19)
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Of the 52 patients who reported diplopia at baseline, 15
patients (29%) noted an improvement after RT (Table 3).
Two patients reported the development of new diplopia
following RT. The median reduction in proptosis during
follow-up, measured using an exophthalmometer, was 2.5
mm and 2 mm in the left and right eyes, respectively. Of the
37 patients with decreased visual acuity at baseline, 30
patients (81%) had improvement in visual acuity following
RT. Twenty-nine of 50 (58%) patients with documented
restriction in extraocular movements had improvement
following RT but 5 patients reported increased limitation in
extraocular movement in at least 1 additional direction
following RT.
Surgical intervention
A total of 29 patients had surgical intervention after RT.
The majority of patients received muscle-corrective (14
patients). There were 5 patients who received orbital
decompression, 2 of whom required this procedure
urgently following RT failure.Discussion
Our study evaluated the efficacy of RT in terms of the
patient’s ability to taper glucocorticoids without any
further exacerbations of orbitopathy symptoms as the
primary outcome measure. It has been recognized that
prolonged use of high-dose corticosteroid therapy can
significantly impact quality of life and treatment-related
morbidity. Long-term and high-dose glucocorticoid ther-
apy can impact nearly every system, resulting in a number
of common bothersome symptoms and medical conditions
including insomnia, acne, skin thinning, weight gain, and
changes in appearance (cushingoid features, hirsutism),
mood problems, proximal muscle weakness, hyperglyce-
mia, and hypertension.16-18 Over 90% of patients taking
glucocorticoids report experiencing at least 1 adverse
event related to therapy and 55% of patients reported at
least 1 adverse event that was very bothersome.19 In our
study, the majority of patients on corticosteroids prior to
RT had dramatic reductions in corticosteroid requirements,
including complete discontinuation of corticosteroids in
91% of patients following RT. This was in keeping with
studies that analyzed steroid requirements as secondary
outcome measures of RT efficacy at specified time
points.20,21 This highlights the role of RT to stabilize the
disease process and minimize the duration of corticoste-
roid therapy and its associated side effects.
The role of radiation therapy in the treatment of Graves’
ophthalmopathy has remained controversial due to
incongruent trial results. Two contributing factors tothese inconsistent trial results include the variable primary
outcome measures used to evaluate the efficacy of RT and
inclusion of patients at all stages of their disease. In part,
this stems from our limited understanding of the
underlying pathogenesis and natural history of Graves’
ophthalmopathy and the therapeutic mechanisms of RT in
this condition.
Graves’ ophthalmopathy is an autoimmune disease
with the following 3 main phases: active phase; plateau or
static phase; and inactivation phase.22 The active phase is
characterized by periorbital and orbital inflammation,
leading to volume increase of extraorbital muscles and
orbital adipose tissue. This pathophysiology accounts for
the clinical presentation of proptosis, diplopia, extraocular
movement restriction, and compressive optic neuropathy
with a risk of decreased visual acuity. It is during this
active phase that medical treatment, corticosteroids and
RT, is thought to be most effective, highlighting the
importance of early intervention, possibly within the first
year of onset of symptoms.22 Remission during the
inactivation phase can occur spontaneously but the patient
can often be left with residual cosmetic or functional
changes. Therefore, patients in the inactivation phase will
often require surgery to have improvements in their orbital
and visual symptoms and quality of life.22 This empha-
sizes the importance of early consideration of RT in
patients with GO who are not responding to corticosteroids
and consideration of outcome measures other than
improvements in orbital and visual symptoms to evaluate
the response of RT.
A recent review on the efficacy and safety of orbital RT
for GO concluded that the combination of orbital RT and
oral glucocorticoids is superior to either alone; also, that
most interventions, including orbital RT, are most
effective during the active phase of disease such that the
inclusion of patients with late GO in intervention clinical
trials can underestimate the efficacy of intervention.23
Consistent with our study findings, this review concluded
that RT significantly reduced the need for further
treatment, including further steroid or immunosuppressive
therapy.23,24
Prospective studies comparing RT with sham irradia-
tion and comparing RT with corticosteroids for GO
reporting variable responses to RT have generally included
patients at all phases of disease and have largely aimed at
measuring response to ocular symptoms.13,14,24 A recent
meta-analysis of prospective studies did not show a
difference between RT and sham RT, based on changes
in the clinical activity score (CAS, a validated scoring
system based on signs of inflammation such as pain,
redness, swelling, and impaired function), but did show
that RT yielded a higher response rate for diplopia with an
odds ratio of 4.88.15 This meta-analysis concluded that
orbital RT as a sole treatment modality for GO remains
controversial, but RT in combination with corticosteroids
has greater efficacy than either treatment alone.12,15 A
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included only 2 studies in their meta-analysis due to the
large heterogeneity of outcome measures in prior trials,
concluded that RT was superior to sham RT but RT was
not significantly better than oral corticosteroids.25 The
individual studies included in this review suggested that
RT in combination with corticosteroids was more effective
than corticosteroids alone, but a meta-analysis was not
performed because of the variable response measures used
in the studies. This review emphasized the need for
reproducible and consistent outcome measures in future
studies so that proper analyses, interpretations, and
comparisons could be performed.
Orbital RT is generally well tolerated with few adverse
effects, as noted in our retrospective review. With
approximately 11 years of follow-up after orbital RT for
GO, prior studies found no associated increase in
secondary malignancy or difference in overall surviv-
al.26,27 Although these follow-up studies were relatively
small and duration of follow-up was limited, they suggest
that the risk of developing a secondary malignancy due to
RT is likely low. Furthermore, the risk of cataracts from
low-dose RT for GO also appears low, based on prior
retrospective studies that have reported similar prevalence
of cataracts in patients treated with corticosteroids for GO,
patients treated with low-dose RT for GO (20 Gy in 10
fractions), and the general population.28 Again, it is
recognized that it is difficult to derive the actual risk of
cataracts due to RT from retrospective studies due to
confounding factors that can contribute to cataract
formation in the study populations (eg, age, sun exposure,
corticosteroid use). An increased incidence of retinopathy
has been observed in patients with existing microvascular
retinopathy following radiation therapy with 20 Gy in 10
fractions.29 Patients with both diabetes and hypertension
may have a slightly increased risk of developing
retinopathy, although the incidence is very small in prior
studies with long-term follow-up.26,28
In attempts to minimize radiation-related toxicities and
potentially improve treatment efficacy, alternative dose
and fractionation schedules have been evaluated, including
20 Gy in 20 fractions, 10 Gy in 10 fractions, 16 Gy in
8 fractions, and 2.4 Gy in 8 fractions. Prospective studies
comparing these dose and fractionation schedules have
shown similar responses, but these studies are small and
the endpoints for therapeutic responses were again
variable.30,31 Nonetheless, low-dose radiation has been
suggested to have a greater inhibitory effect on the
inflammatory response and the nitric oxide pathway, and
given the greater risk of retinopathy with higher radiation
doses, these studies provoke further investigation of lower
dose RT for GO.
Given the retrospective nature of our study, there were
limitations in the duration and completeness of clinical
follow-up. The mean in-clinic follow-up was relatively
short at 9.3 months, and it is possible that corticosteroiddose reductions may not have been sustained after patients
were discharged. Efforts were made to capture any late
increases in corticosteroid dose by providing clear
instructions to return to clinic with any recurrent
symptoms for patients who were discharged to their
referring physician. A total of 11 patients were censored
from the final data analysis due to missing documentation
of corticosteroids or loss to follow-up (ie, failing to fulfill
the specified criteria for planned transition of care).
Smoking status, which is recognized as an important
prognostic factor associated with disease activity and
predictive factor for response to therapy, was not
consistently available and therefore could not be included
in our analyses. Finally, as baseline CAS or disease
activity was not consistently reported in this cohort, the
severity and natural course of disease for patients in this
study may have been variable. Although the majority of
our patients were referred for consideration of RT only
after failing corticosteroid tapering, it is possible that a
proportion of the patients may have successfully tapered
off corticosteroids without RT. However, timely success-
ful taper off corticosteroids following combined therapy
without late exacerbations of orbitopathy is supported by
existing literature.Conclusions
This study suggests that orbital radiation therapy helps
minimize the dose and duration of corticosteroid therapy
for patients with Graves’ ophthalmopathy while improving
ocular symptoms. The ability to shorten the duration of
corticosteroid therapy will minimize steroid-related com-
plications and thereby improve patient quality of life.
Given the clinical impact and the proposed mechanism of
RT, future prospective studies should consider evaluating
corticosteroid requirement as a measure of efficacy of
orbital RT for GO. Consistent outcome measures and
patient eligibility criteria (accounting for euthyroid state,
smoking status, disease activity scored using the CAS, and
incorporation of patient-reported symptoms) in future
studies are crucial to meaningful interpretation of RT trials
for Graves’ ophthalmopathy.References
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